212 related articles for article (PubMed ID: 23929631)
1. Inhibition of human α-methylacyl CoA racemase (AMACR): a target for prostate cancer.
Carnell AJ; Kirk R; Smith M; McKenna S; Lian LY; Gibson R
ChemMedChem; 2013 Oct; 8(10):1643-7. PubMed ID: 23929631
[TBL] [Abstract][Full Text] [Related]
2. Novel 2-arylthiopropanoyl-CoA inhibitors of α-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Yevglevskis M; Nathubhai A; Wadda K; Lee GL; Al-Rawi S; Jiao T; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2019 Nov; 92():103263. PubMed ID: 31536953
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships.
Petrova YD; Wadda K; Nathubhai A; Yevglevskis M; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2019 Nov; 92():103264. PubMed ID: 31536955
[TBL] [Abstract][Full Text] [Related]
4. New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.
Morgenroth A; Urusova EA; Dinger C; Al-Momani E; Kull T; Glatting G; Frauendorf H; Jahn O; Mottaghy FM; Reske SN; Zlatopolskiy BD
Chemistry; 2011 Aug; 17(36):10144-50. PubMed ID: 21812041
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of rationally designed AMACR 1A inhibitors.
Yevglevskis M; Lee GL; Nathubhai A; Petrova YD; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2018 Sep; 79():145-154. PubMed ID: 29751320
[TBL] [Abstract][Full Text] [Related]
6. Potent dialkyl substrate-product analogue inhibitors and inactivators of α-methylacyl-coenzyme A racemase from Mycobacterium tuberculosis by rational design.
Pal M; Easton NM; Yaphe H; Bearne SL
Bioorg Chem; 2018 Apr; 77():640-650. PubMed ID: 29502025
[TBL] [Abstract][Full Text] [Related]
7. A study on the AMACR catalysed elimination reaction and its application to inhibitor testing.
Yevglevskis M; Lee GL; Sun J; Zhou S; Sun X; Kociok-Köhn G; James TD; Woodman TJ; Lloyd MD
Org Biomol Chem; 2016 Jan; 14(2):612-622. PubMed ID: 26537174
[TBL] [Abstract][Full Text] [Related]
8. A continuous assay for alpha-methylacyl-coenzyme A racemase using circular dichroism.
Ouazia D; Bearne SL
Anal Biochem; 2010 Mar; 398(1):45-51. PubMed ID: 19854148
[TBL] [Abstract][Full Text] [Related]
9. A novel colorimetric assay for α-methylacyl-CoA racemase 1A (AMACR; P504S) utilizing the elimination of 2,4-dinitrophenolate.
Yevglevskis M; Lee GL; Nathubhai A; Petrova YD; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Chem Commun (Camb); 2017 May; 53(37):5087-5090. PubMed ID: 28338138
[TBL] [Abstract][Full Text] [Related]
10. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors.
Carnell AJ; Hale I; Denis S; Wanders RJ; Isaacs WB; Wilson BA; Ferdinandusse S
J Med Chem; 2007 May; 50(11):2700-7. PubMed ID: 17477519
[TBL] [Abstract][Full Text] [Related]
12. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Zha S; Isaacs WB
Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877
[TBL] [Abstract][Full Text] [Related]
13. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
14. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA; Chinnaiyan AM
Am J Pathol; 2004 Mar; 164(3):787-93. PubMed ID: 14982833
[TBL] [Abstract][Full Text] [Related]
15. Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.
Festuccia C; Gravina GL; Mancini A; Muzi P; Cesare ED; Kirk R; Smith M; Hughes S; Gibson R; Lian LY; Ricevuto E; Carnell AJ
Anticancer Agents Med Chem; 2014; 14(7):1031-41. PubMed ID: 24712326
[TBL] [Abstract][Full Text] [Related]
16. Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2201-2210. PubMed ID: 28741117
[TBL] [Abstract][Full Text] [Related]
17. A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
Kovaleva OV; Samoilova DV; Shitova MS; Oleinikova NA; Danilova NV; Malkov PG; Gratchev A
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):30-34. PubMed ID: 28234557
[TBL] [Abstract][Full Text] [Related]
18. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
[TBL] [Abstract][Full Text] [Related]
19. Analysis of enzyme reactions using NMR techniques: A case study with α-methylacyl-CoA racemase (AMACR).
Woodman TJ; Lloyd MD
Methods Enzymol; 2023; 690():159-209. PubMed ID: 37858529
[TBL] [Abstract][Full Text] [Related]
20. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Mobley JA; Leav I; Zielie P; Wotkowitz C; Evans J; Lam YW; L'Esperance BS; Jiang Z; Ho SM
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):775-83. PubMed ID: 12917210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
